Australia's Recce partners Indonesia's Etana Biotech to advance anti-infective R&D, manufacturing

08 February 2024 | News

MoU signed to facilitate late-stage clinical trials in Indonesia, supporting the Indonesian Government's access to novel infectious disease medicines

Recce Pharmaceuticals Limited, the Company developing a New Class of Synthetic Anti-Infectives, has signed Memorandum of Understanding (MoU) with PT Etana Biotechnologies (Etana), a leading Indonesian biomedical organisation, to accelerate the clinical development of Recce's anti-infective portfolio across Indonesia, with the aim of addressing the critical global health challenge of antimicrobial resistance (AMR).

The significant bilateral initiative supported by the Australian and Indonesian Governments. In a meeting together with Senior Executives from Recce and Etana, Her Excellency Penny Williams PSM, the Australian Ambassador to Indonesia, the Indonesian Minister of Health, Budi Sadikin, and the Head of the National Research and Innovation Agency (BRIN), all were in full support of this initiative.

The key objectives of the partnership is to collaborate with nationally selected biotech sponsor Etana to advance Recce's clinical program with speed, accessibility, cost-effectiveness (incl. substantial Government support), and quality. By coordinating bilateral efforts between Australia and Indonesia Governments and industry experts, this will provide Recce with market entry and penetration for international expansion in newly developed wealth of opportunities.

Chief Executive Officer of Recce Pharmaceuticals, James Graham, said, "This Bilateral Collaboration between Recce and Etana, signifies the Australian and Indonesian Governments' shared commitment to advancing public health, fostering innovation, and addressing the global challenge of AMR in the Asia Pacific region. By combining our expertise and resources, we can make significant strides towards a healthier and more resilient future for both our nations and the global community."